White label ELPA - ClinicalTrials.eu

Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

Not recruiting

3 1 1 1
Investigated diseases:
- Acute myeloid leukaemia
Investigated drugs:
- Azacitidine
- Venetoclax
+1
Study on Nicotine Freshmint Mouthspray for E-cigarette Users Looking to Quit

Not recruiting

3 1 1
Investigated diseases:
- Nicotine dependence
Investigated drugs:
- Nicotine
Study on Andexanet Alfa for Patients on Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Needing Urgent Surgery to Reduce Bleeding Risk

Not recruiting

3 1 1 1
Investigated drugs:
+13
Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Not recruiting

3 1 1 1
Investigated diseases:
- Plasma cell myeloma
Investigated drugs:
+1
Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

Not recruiting

2 1 1 1
Investigated diseases:
- Diffuse large B-cell lymphoma
Investigated drugs:
Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Not recruiting

3 1
Investigated diseases:
- Psoriatic arthropathy
Investigated drugs:
- Deucravacitinib
+4
Study on the Effects of Tiotropium Bromide Gel for Patients with Severe Hand Sweating

Not recruiting

2 1
Investigated diseases:
- Hyperhidrosis
Investigated drugs:
- Tiotropium Bromide Monohydrate
Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Not recruiting

2 1 1 1
Investigated diseases:
- Non-small cell lung cancer
Investigated drugs:
Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer stage IIIB
- Non-small cell lung cancer
Investigated drugs:
- Crizotinib
- Repotrectinib
+4
Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

Not recruiting

3 1 1 1
Investigated diseases:
- HER2 positive breast cancer
- Hormone receptor positive breast cancer
Investigated drugs:
- Pertuzumab
- Trastuzumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies